KR100911779B1 - 모다피닐을 포함하는 고형 제약 제제 - Google Patents

모다피닐을 포함하는 고형 제약 제제 Download PDF

Info

Publication number
KR100911779B1
KR100911779B1 KR1020037015397A KR20037015397A KR100911779B1 KR 100911779 B1 KR100911779 B1 KR 100911779B1 KR 1020037015397 A KR1020037015397 A KR 1020037015397A KR 20037015397 A KR20037015397 A KR 20037015397A KR 100911779 B1 KR100911779 B1 KR 100911779B1
Authority
KR
South Korea
Prior art keywords
weight
modafinil
mixture
composition
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037015397A
Other languages
English (en)
Korean (ko)
Other versions
KR20040005986A (ko
Inventor
빈센트 코배리
조지 그랜돌피
알파 파리크
Original Assignee
세파론, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26852708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100911779(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세파론, 인코포레이티드 filed Critical 세파론, 인코포레이티드
Publication of KR20040005986A publication Critical patent/KR20040005986A/ko
Application granted granted Critical
Publication of KR100911779B1 publication Critical patent/KR100911779B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020037015397A 2001-05-25 2002-05-23 모다피닐을 포함하는 고형 제약 제제 Expired - Fee Related KR100911779B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29369501P 2001-05-25 2001-05-25
US60/293,695 2001-05-25
US10/155,913 US7297346B2 (en) 2001-05-25 2002-05-23 Pharmaceutical formulations of modafinil
US10/155,913 2002-05-23
PCT/US2002/016369 WO2002096401A1 (en) 2001-05-25 2002-05-24 Solid pharmaceutical formulations comprising modafinil

Publications (2)

Publication Number Publication Date
KR20040005986A KR20040005986A (ko) 2004-01-16
KR100911779B1 true KR100911779B1 (ko) 2009-08-12

Family

ID=26852708

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037015397A Expired - Fee Related KR100911779B1 (ko) 2001-05-25 2002-05-23 모다피닐을 포함하는 고형 제약 제제

Country Status (19)

Country Link
US (1) US7297346B2 (enExample)
EP (1) EP1397127B8 (enExample)
JP (1) JP4443119B2 (enExample)
KR (1) KR100911779B1 (enExample)
CN (1) CN1318026C (enExample)
AT (1) ATE357228T1 (enExample)
AU (1) AU2002318155B8 (enExample)
BR (1) BRPI0210085B8 (enExample)
CA (1) CA2448456C (enExample)
DE (1) DE60219005T2 (enExample)
ES (1) ES2281527T3 (enExample)
IL (1) IL158959A (enExample)
MX (1) MXPA03010705A (enExample)
MY (1) MY129376A (enExample)
NO (1) NO328805B1 (enExample)
NZ (1) NZ530040A (enExample)
TW (1) TWI321475B (enExample)
WO (1) WO2002096401A1 (enExample)
ZA (1) ZA200309978B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101081212B1 (ko) 2000-07-27 2011-11-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질의 순수한 모다피닐 및 이의 제조 방법
WO2002064093A2 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2006121552A2 (en) * 2005-04-08 2006-11-16 New River Pharmaceuticals Inc. Abuse-resistant amphetamine prodrugs
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20080044468A1 (en) * 2002-07-25 2008-02-21 Romi Barat Singh Processes For The Preparation Of Oral Dosage Formulations Of Modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
US20070066996A1 (en) * 2003-03-17 2007-03-22 Katzman Daniel E Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
CN101031290B (zh) * 2003-09-18 2011-09-21 赛福伦公司 改良释放的莫达非尼药物组合物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
KR101431711B1 (ko) * 2008-05-07 2014-08-21 삼성전자 주식회사 발광 장치 및 발광 시스템의 제조 방법, 상기 방법을이용하여 제조한 발광 장치 및 발광 시스템
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
DK2649187T3 (da) 2010-12-08 2018-01-29 Codexis Inc Biokatalysatorer og fremgangsmåder til syntesen af armodafinil
WO2012084759A2 (en) * 2010-12-21 2012-06-28 Akzo Nobel Chemicals International B.V. Instant powders for aqueous cosmetic applications
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2001013906A2 (en) * 1999-08-20 2001-03-01 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) * 1923-11-20 1926-01-26 William A Cook Spring-forming die
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) * 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
FR2702968B1 (fr) * 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2706767B1 (enExample) * 1993-06-22 1995-09-08 Lafon Labor
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
JP2001515854A (ja) * 1997-09-11 2001-09-25 ニュコメデ ダンマルク アクティーゼルスカブ 非ステロイド性抗炎症薬物質（ＮＳＡＩＤｓ）の改良された開放性多重−単位組成物
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2001013906A2 (en) * 1999-08-20 2001-03-01 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation

Also Published As

Publication number Publication date
NZ530040A (en) 2005-11-25
JP2004532863A (ja) 2004-10-28
NO20035211D0 (no) 2003-11-24
AU2002318155B2 (en) 2007-03-01
US7297346B2 (en) 2007-11-20
CN1511031A (zh) 2004-07-07
DE60219005D1 (de) 2007-05-03
MXPA03010705A (es) 2004-05-27
EP1397127B1 (en) 2007-03-21
KR20040005986A (ko) 2004-01-16
BRPI0210085B1 (pt) 2020-11-10
HK1061652A1 (en) 2004-09-30
DE60219005T2 (de) 2007-12-13
NO328805B1 (no) 2010-05-18
BRPI0210085A (pt) 2004-06-29
US20030022940A1 (en) 2003-01-30
MY129376A (en) 2007-03-30
JP4443119B2 (ja) 2010-03-31
IL158959A (en) 2010-06-30
BRPI0210085B8 (pt) 2021-07-20
EP1397127B8 (en) 2008-02-20
WO2002096401A1 (en) 2002-12-05
TWI321475B (en) 2010-03-11
CA2448456C (en) 2010-07-27
CA2448456A1 (en) 2002-12-05
ATE357228T1 (de) 2007-04-15
ZA200309978B (en) 2005-05-25
CN1318026C (zh) 2007-05-30
ES2281527T3 (es) 2007-10-01
AU2002318155B8 (en) 2008-05-15
EP1397127A1 (en) 2004-03-17
IL158959A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
KR100911779B1 (ko) 모다피닐을 포함하는 고형 제약 제제
JP2014028833A (ja) モダフィニルの新規の医薬製剤
AU2002318155A1 (en) Solid pharmaceutical formulations comprising modafinil
US20120010216A1 (en) Pharmaceutical compositions containing vanoxerine
US20100129444A1 (en) Novel Pharmaceutical Formulations of Modafinil
HK1078265B (en) Novel pharmaceutical formulations of modafinil
HK1061652B (en) Solid pharmaceutical formulations comprising modafinil

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20120730

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130725

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140724

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150805

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150805

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301